Government-Owned Inventions; Availability for Licensing, 17268 [2017-07057]
Download as PDF
17268
Federal Register / Vol. 82, No. 67 / Monday, April 10, 2017 / Notices
needs of professionals caring for
children in disasters since the 2011
National Center for Disaster Medicine
and Public Health Conference on this
topic. We will post modifications to the
agenda on the NACCD May 5, 2017
meeting Web page, which is located at
https://www.phe.gov/naccd.
Availability of Materials: We will post
all meeting materials prior to the
meeting on the NACCD May 5, 2017
meeting Web page located at https://
www.phe.gov/naccd.
Procedures for Providing Public Input:
Members of the public may attend the
teleconference using a toll-free call-in
phone number available on the NACCD
Web site at https://www.phe.gov/naccd.
We encourage members of the public to
provide written comments that are
relevant to the NACCD teleconference
prior to May 5, 2017. Send written
comments by email via the ‘‘Contact
Us’’ link on https://www.phe.gov/naccd
with ‘‘NACCD Public Comment’’ in the
subject line. The NACCD will respond
to comments received by close-ofbusiness April 28, 2017, during the
meeting.
Dated: April 4, 2017.
George W. Korch Jr.,
Acting Assistant Secretary for Preparedness
and Response.
[FR Doc. 2017–07052 Filed 4–7–17; 8:45 am]
BILLING CODE P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
patent applications listed below may be
obtained by communicating with the
indicated licensing contact Peter Soukas
at the Technology Transfer and
Intellectual Property Office, National
Institute of Allergy and Infectious
Diseases, 5601 Fishers Lane, Rockville,
asabaliauskas on DSK3SPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
20:02 Apr 07, 2017
Jkt 241001
MD 20852; tel. 301–496–2644. A signed
Confidential Disclosure Agreement will
be required to receive copies of
unpublished patent applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
A Full-Length Infectious cDNA Clone of
Zika Virus From the 2015 Epidemic in
Brazil as a Genetic Platform for Studies
of Virus-Host Interactions and Vaccine
Development
Description of Technology: An
arthropod-borne virus, Zika virus
(ZIKV), has recently emerged as a major
human pathogen. Associated with
complications during perinatal
´
development and Guillain-Barre
syndrome in adults, ZIKV raises new
challenges for understanding the
molecular determinants of flavivirus
pathogenesis. This underscores the
necessity for the development of a
reverse genetic system based on an
epidemic ZIKV strain. This technology
relates to the generation and
characterization in cell cultures of an
infectious cDNA clone of ZIKV isolated
from the 2015 epidemic in Brazil. The
cDNA-derived ZIKV replicated
efficiently in a variety of cell lines,
including those of both neuronal and
placental origin. It was observed that the
growth of cDNA-derived virus was
attenuated compared to the growth of
the parental isolate in most cell lines,
which correlates with substantial
differences in sequence heterogeneity
between these viruses that were
determined by deep-sequencing
analysis. Moreover, these results
indicate that caution should be
exercised when interpreting the results
of reverse-genetics experiments in
attempts to accurately predict the
biology of natural viruses. Finally, a
Vero cell-adapted cDNA clone of ZIKV
was generated that can be used as a
convenient platform for studies aimed at
the development of ZIKV vaccines (live
attenuated and inactivated) and
therapeutics.
This technology is available for
licensing nonexclusively in accordance
with 35 U.S.C. 209 and 37 CFR part 404,
as well as for further development and
evaluation under a research
collaboration.
This technology is further described
in Tsetsarkin et al., ‘‘A Full-Length
Infectious cDNA Clone of Zika Virus
from the 2015 Epidemic in Brazil as a
Genetic Platform for Studies of VirusHost Interactions and Vaccine
Development,’’ mBio. 2016 Jul–Aug;
7(4): e01114–16. Published online 2016
Aug 23. doi: 10.1128/mBio.01114–16.
Potential Commercial Applications:
PO 00000
Frm 00091
Fmt 4703
Sfmt 4703
• Diagnostics
• Vaccines
• Development of therapeutics
Competitive Advantages:
• Use in development of flavivirus
vaccines
• Virus growth in various cell lines
• Developing and developed world
research tool
Development Stage:
• Research materials
Inventors: Alexander Pletnev (NIAID),
Konstantin Tsetsarkin (NIAID).
Intellectual Property: HHS Reference
No. E–114–2017/0.
Licensing Contact: Peter Soukas, J.D.,
301–594–8730; peter.soukas@nih.gov.
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize vaccine(s) or diagnostics
for prophylaxis against flavivirus
infections. For collaboration
opportunities, please contact Peter
Soukas, J.D., 301–594–8730;
peter.soukas@nih.gov.
Dated: March 23, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2017–07057 Filed 4–7–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
U.S. patent applications listed below
may be obtained by communicating
with the indicated licensing contact
James M. Robinson at the Technology
Transfer and Intellectual Property
Office, National Institute of Allergy and
SUMMARY:
E:\FR\FM\10APN1.SGM
10APN1
Agencies
[Federal Register Volume 82, Number 67 (Monday, April 10, 2017)]
[Notices]
[Page 17268]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-07057]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information and copies of
the patent applications listed below may be obtained by communicating
with the indicated licensing contact Peter Soukas at the Technology
Transfer and Intellectual Property Office, National Institute of
Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD
20852; tel. 301-496-2644. A signed Confidential Disclosure Agreement
will be required to receive copies of unpublished patent applications.
SUPPLEMENTARY INFORMATION: Technology description follows.
A Full-Length Infectious cDNA Clone of Zika Virus From the 2015
Epidemic in Brazil as a Genetic Platform for Studies of Virus-Host
Interactions and Vaccine Development
Description of Technology: An arthropod-borne virus, Zika virus
(ZIKV), has recently emerged as a major human pathogen. Associated with
complications during perinatal development and Guillain-Barr[eacute]
syndrome in adults, ZIKV raises new challenges for understanding the
molecular determinants of flavivirus pathogenesis. This underscores the
necessity for the development of a reverse genetic system based on an
epidemic ZIKV strain. This technology relates to the generation and
characterization in cell cultures of an infectious cDNA clone of ZIKV
isolated from the 2015 epidemic in Brazil. The cDNA-derived ZIKV
replicated efficiently in a variety of cell lines, including those of
both neuronal and placental origin. It was observed that the growth of
cDNA-derived virus was attenuated compared to the growth of the
parental isolate in most cell lines, which correlates with substantial
differences in sequence heterogeneity between these viruses that were
determined by deep-sequencing analysis. Moreover, these results
indicate that caution should be exercised when interpreting the results
of reverse-genetics experiments in attempts to accurately predict the
biology of natural viruses. Finally, a Vero cell-adapted cDNA clone of
ZIKV was generated that can be used as a convenient platform for
studies aimed at the development of ZIKV vaccines (live attenuated and
inactivated) and therapeutics.
This technology is available for licensing nonexclusively in
accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for
further development and evaluation under a research collaboration.
This technology is further described in Tsetsarkin et al., ``A
Full-Length Infectious cDNA Clone of Zika Virus from the 2015 Epidemic
in Brazil as a Genetic Platform for Studies of Virus-Host Interactions
and Vaccine Development,'' mBio. 2016 Jul-Aug; 7(4): e01114-16.
Published online 2016 Aug 23. doi: 10.1128/mBio.01114-16.
Potential Commercial Applications:
Diagnostics
Vaccines
Development of therapeutics
Competitive Advantages:
Use in development of flavivirus vaccines
Virus growth in various cell lines
Developing and developed world research tool
Development Stage:
Research materials
Inventors: Alexander Pletnev (NIAID), Konstantin Tsetsarkin
(NIAID).
Intellectual Property: HHS Reference No. E-114-2017/0.
Licensing Contact: Peter Soukas, J.D., 301-594-8730;
peter.soukas@nih.gov.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate or commercialize vaccine(s) or diagnostics for
prophylaxis against flavivirus infections. For collaboration
opportunities, please contact Peter Soukas, J.D., 301-594-8730;
peter.soukas@nih.gov.
Dated: March 23, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2017-07057 Filed 4-7-17; 8:45 am]
BILLING CODE 4140-01-P